Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Sep 2025 Status changed from planning to recruiting.
27 Jul 2025 According to a Genentech media release, Roche's Elecsys pTau217 is a blood-based biomarker test for rule-in and rule-out diagnosis of Alzheimer's amyloid pathology which has received Breakthrough Device Designation from USFDA will also be utilized in Roche's TRONTIER studies.
27 Jul 2025 According to a Genentech media release, design of the Phase III TRONTIER 1 and 2 studies will be presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com